Related Topics:
Facility ID: 95688LZCRP700EU
Facility Name and Address: ALZA CORP 700 EUBANKS DRIVE VACAVILLE, CA 95688 Parent Company: JOHNSON & JOHNSON INC Industry: Pharmaceutical Preparation Manufacturing (325412) Chemical: Nicotine and salts Reports: View TRI Facility profile report for this facility View TRI Form R submissions by this facility |
|
*You can navigate within the map with your mouse. |
Production Related Waste Management for Selected Chemical
lchemid=N503
Chart Options1: |
Waste Management Comparison -
Display facility comparison report for this industry and chemical
Display facility comparison report for this parent company
Pollution Prevention Activities for Selected Chemical
Reporting Year | Section 8.10: Newly Implemented Source Reduction Activity | Section 8.10: Methods to Identify Activity | Section 8.11: Optional Pollution Prevention Information* |
---|---|---|---|
2021 |
Barriers: B7-Barriers to P2 B7 - No known substitutes or alternative technologies.
|
Barriers to P2: B7 - No known substitutes or alternative technologies. - The product is nicotine patches. |
|
2020 |
Barriers: B6-Barriers to P2 B6 - Pollution prevention previously implemented - additional reduction does not appear technically or economically feas
|
Barriers to P2: B6 - Pollution prevention previously implemented - additional reduction does not appear technically or economically feas - No further process efficiencies will be pursued, as facility is scheduled for closure in Q1 2022 |
|
2019 |
Barriers: B6-Barriers to P2 B6 - Pollution prevention previously implemented - additional reduction does not appear technically or economically feas
|
Barriers to P2: B6 - Pollution prevention previously implemented - additional reduction does not appear technically or economically feas - Process efficiency improvements have previously reduced waste webbing significantly, yield losses have decreased as a result of these improvements. No additional reduction options have been identified. |
|
2018 |
Barriers: B6-Barriers to P2 B6 - Pollution prevention previously implemented - additional reduction does not appear technically or economically feas
Barriers: B7-Barriers to P2 B7 - No known substitutes or alternative technologies. |
Barriers to P2: B6 - Pollution prevention previously implemented - additional reduction does not appear technically or economically feas - All technically and economically feasible methods for reducing waste generation from manufacturing process have been implemented, no additional methods have been identified at this time. Barriers to P2: B7 - No known substitutes or alternative technologies. - Nicotine is the active ingredient in the product, so it cannot be substituted. |
|
2017 |
Barriers: B7-Barriers to P2 B7 - No known substitutes or alternative technologies.
|
Barriers to P2: B7 - No known substitutes or alternative technologies. - FDA approved manufacturing process |
|
2016 |
Other Barriers to Source Reduction - FDA regulated process |
||
2015 |
Barriers: B5-Barriers to P2 B5 - Specific regulatory/permit burdens.
|
Barriers to P2: B5 - Specific regulatory/permit burdens. - Active Pharmaceutical Ingredient, FDA restrictions on concentration. |
|
2014 |
Barriers: B7-Barriers to P2 B7 - No known substitutes or alternative technologies.
|
Barriers to P2: B7 - No known substitutes or alternative technologies. - Chemical is the active ingredient in the product, concentration is dictated by FDA regulated formulas. Source Reduction: General Environmental Management - Manufacturing and waste management procedures reduce errors and thus reduce waste generated from errors. |
|
2013 |
Other Barriers to Source Reduction - Pollution prevention previously implemented - additional reduction does not appear technically or economically feasible |
||
2009 |
Source Reduction:: W58: Other process modifications
|
Methods to Identify SR Opportunities: T04: Participative team management
|